SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Paterson Ross) "

Sökning: WFRF:(Paterson Ross)

  • Resultat 21-27 av 27
  • Föregående 12[3]
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
21.
  • Paterson, Ross W, et al. (författare)
  • Cerebrospinal fluid in the differential diagnosis of Alzheimer's disease: clinical utility of an extended panel of biomarkers in a specialist cognitive clinic
  • 2018
  • Ingår i: Alzheimer's research & therapy. - 1758-9193. ; 10, s. 1-11
  • Tidskriftsartikel (refereegranskat)abstract
    • Cerebrospinal fluid (CSF) biomarkers are increasingly being used to support a diagnosis of Alzheimer's disease (AD). Their clinical utility for differentiating AD from non-AD neurodegenerative dementias, such as dementia with Lewy bodies (DLB) or frontotemporal dementia (FTD), is less well established. We aimed to determine the diagnostic utility of an extended panel of CSF biomarkers to differentiate AD from a range of other neurodegenerative dementias.We used immunoassays to measure conventional CSF markers of amyloid and tau pathology (amyloid beta (Aβ)1-42, total tau (T-tau), and phosphorylated tau (P-tau)) as well as amyloid processing (AβX-38, AβX-40, AβX-42, soluble amyloid precursor protein (sAPP)α, and sAPPβ), large fibre axonal degeneration (neurofilament light chain (NFL)), and neuroinflammation (YKL-40) in 245 patients with a variety of dementias and 30 controls. Patients fulfilled consensus criteria for AD (n = 156), DLB (n = 20), behavioural variant frontotemporal dementia (bvFTD; n = 45), progressive non-fluent aphasia (PNFA; n = 17), and semantic dementia (SD; n = 7); approximately 10% were pathology/genetically confirmed (n = 26). Global tests based on generalised least squares regression were used to determine differences between groups. Non-parametric receiver operating characteristic (ROC) curves and area under the curve (AUC) analyses were used to quantify how well each biomarker discriminated AD from each of the other diagnostic groups (or combinations of groups). CSF cut-points for the major biomarkers found to have diagnostic utility were validated using an independent cohort which included causes of AD (n = 104), DLB (n = 5), bvFTD (n = 12), PNFA (n = 3), SD (n = 9), and controls (n = 10).There were significant global differences in Aβ1-42, T-tau, T-tau/Aβ1-42 ratio, P-tau-181, NFL, AβX-42, AβX-42/X-40 ratio, APPα, and APPβ between groups. At a fixed sensitivity of 85%, AβX-42/X-40 could differentiate AD from controls, bvFTD, and SD with specificities of 93%, 85%, and 100%, respectively; for T-tau/Aβ1-42 these specificities were 83%, 70%, and 86%. AβX-42/X-40 had similar or higher specificity than Aβ1-42. No biomarker or ratio could differentiate AD from DLB or PNFA with specificity > 50%. Similar sensitivities and specificities were found in the independent validation cohort for differentiating AD and other dementias and in a pathology/genetically confirmed sub-cohort.CSF AβX-42/X-40 and T-tau/Aβ1-42 ratios have utility in distinguishing AD from controls, bvFTD, and SD. None of the biomarkers tested had good specificity at distinguishing AD from DLB or PNFA.
  •  
22.
  • Paterson, Ross W, et al. (författare)
  • Dissecting IWG-2 typical and atypical Alzheimer's disease: insights from cerebrospinal fluid analysis.
  • 2015
  • Ingår i: Journal of neurology. - 1432-1459. ; 262, s. 2722-2730
  • Tidskriftsartikel (refereegranskat)abstract
    • Pathobiological factors underlying phenotypic diversity in Alzheimer's disease (AD) are incompletely understood. We used an extended cerebrospinal fluid (CSF) panel to explore differences between "typical" with "atypical" AD and between amnestic, posterior cortical atrophy, logopenic aphasia and frontal variants. We included 97 subjects fulfilling International Working Group-2 research criteria for AD of whom 61 had "typical" AD and 36 "atypical" syndromes, and 30 controls. CSF biomarkers included total tau (T-tau), phosphorylated tau (P-tau), amyloid β1-42, amyloid βX-38/40/42, YKL-40, neurofilament light (NFL), and amyloid precursor proteins α and β. The typical and atypical groups were matched for age, sex, severity and rate of cognitive decline and had similar biomarker profiles, with the exception of NFL which was higher in the atypical group (p = 0.03). Sub-classifying the atypical group into its constituent clinical syndromes, posterior cortical atrophy was associated with the lowest T-tau [604.4 (436.8-675.8) pg/mL], P-tau (79.8 ± 21.8 pg/L), T-tau/Aβ1-42 ratio [2.3 (1.4-2.6)], AβX-40/X-42 ratio (22.1 ± 5.8) and rate of cognitive decline [1.9 (0.75-4.25) MMSE points/year]. Conversely, the frontal variant group had the highest levels of T-tau [1185.4 (591.7-1329.3) pg/mL], P-tau (116.4 ± 45.4 pg/L), T-tau/Aβ1-42 ratio [5.2 (3.3-6.9)] and AβX-40/X-42 ratio (27.9 ± 7.5), and rate of cognitive decline. Whilst on a group level IWG-2 "typical" and "atypical" AD share similar CSF profiles, which are very different from controls, atypical AD is a heterogeneous entity with evidence for subtle differences in amyloid processing and neurodegeneration between different clinical syndromes. These findings also have practical implications for the interpretation of clinical CSF biomarker results.
  •  
23.
  •  
24.
  • Toombs, Jamie, et al. (författare)
  • Amyloid-beta 42 adsorption following serial tube transfer.
  • 2014
  • Ingår i: Alzheimer's research & therapy. - 1758-9193. ; 6:1
  • Tidskriftsartikel (refereegranskat)abstract
    • Cerebrospinal fluid (CSF) amyloid-beta 38 (Aβ38), 40 (Aβ40), 42 (Aβ42) and total tau (T-tau) are finding increasing utility as biomarkers of Alzheimer's disease (AD). The purpose of this study was to determine whether measured CSF biomarker concentrations were affected by transfer of CSF between tubes, and whether addition of a non-ionic surfactant mitigates any observed effects.
  •  
25.
  • Toombs, Jamie, et al. (författare)
  • Identification of an important potential confound in CSF AD studies: aliquot volume.
  • 2013
  • Ingår i: Clinical chemistry and laboratory medicine : CCLM / FESCC. - 1434-6621. ; 51:12
  • Tidskriftsartikel (refereegranskat)abstract
    • Abstract Background: Cerebrospinal fluid (CSF) amyloid beta 1-42 (Aβ1-42), total tau (T-tau) and phosphorylated tau181 (P-tau) are finding increasing utility as biomarkers of Alzheimer's disease (AD). The purpose of this study was to determine whether measured CSF biomarker concentrations were affected by aliquot storage volume and whether addition of detergent-containing buffer mitigates any observed effects. Methods: AD and control CSF was distributed into polypropylene tubes in aliquots of different volumes (50-1500 μL). Aβ1-42, T-tau and P-tau were measured with and without addition of Tween 20 (0.05%). Results: Measured concentrations of Aβ1-42 increased two-fold with aliquot storage volume. A volume increase of 10 µL caused an Aβ1-42 increase of 0.95 pg/mL [95% confidence interval (CI) 0.36-1.50, p=0.02] in controls, and 0.60 pg/mL (CI 0.23-0.98 pg/mL, p=0.003) in AD samples. Following addition of Tween 20, the positive relationship between Aβ1-42 and aliquot volume disappeared. T-tau and P-tau were not significantly affected. Conclusions: CSF aliquot storage volume has a significant impact on the measured concentration of Aβ1-42. The introduction of a buffer detergent at the initial aliquoting stage may be an effective solution to this problem.
  •  
26.
  • Wellington, Henrietta, et al. (författare)
  • Increased CSF neurogranin concentration is specific to Alzheimer disease.
  • 2016
  • Ingår i: Neurology. - 1526-632X. ; 86:9, s. 829-35
  • Tidskriftsartikel (refereegranskat)abstract
    • To assess the specificity of the dendritic protein neurogranin (Ng) in CSF from patients with a broad range of neurodegenerative diseases including a variety of dementias, tauopathies, and synucleinopathies.
  •  
27.
  • Weston, Philip S J, et al. (författare)
  • Diagnosing Dementia in the Clinical Setting: Can Amyloid PET Provide Additional Value Over Cerebrospinal Fluid?
  • 2016
  • Ingår i: Journal of Alzheimer's disease : JAD. - 1875-8908. ; 54:4, s. 1297-1302
  • Tidskriftsartikel (refereegranskat)abstract
    • Cerebrospinal fluid (CSF) measures of amyloid and tau are the first-line Alzheimer's disease biomarkers in many clinical centers. We assessed if and when the addition of amyloid PET following CSF measurements provides added diagnostic value. Twenty patients from a cognitive clinic, who had undergone detailed assessment including CSF measures, went on to have amyloid PET. The treating neurologist's working diagnosis, and degree of diagnostic certainty, was assessed both before and after the PET. Amyloid PET changed the diagnosis in 7/20 cases. Amyloid PET can provide added diagnostic value, particularly in young-onset, atypical dementias, where CSF results are borderline and diagnostic uncertainty remains.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 21-27 av 27
  • Föregående 12[3]
Typ av publikation
tidskriftsartikel (21)
forskningsöversikt (5)
konferensbidrag (1)
Typ av innehåll
refereegranskat (24)
övrigt vetenskapligt (3)
Författare/redaktör
Paterson, Ross W (20)
Schott, Jonathan M (16)
Zetterberg, Henrik, ... (14)
Fox, Nick C (10)
Blennow, Kaj, 1958 (7)
Toombs, Jamie (7)
visa fler...
Paterson, Ross (6)
Lunn, Michael P (5)
Magdalinou, Nadia K (5)
Bernardy, Jean-Phili ... (4)
Jansson, Patrik, 197 ... (4)
Carter, Stephen F. (4)
Betts, Matthew J. (4)
Heslegrave, Amanda (3)
Schöll, Michael (3)
Keshavan, Ashvini (3)
Foiani, Martha S (3)
Brown, J. (2)
Klein, R (2)
Zetterberg, H (2)
Paterson, R (2)
Hardy, John (2)
Hansson, O. (2)
Hansson, Oskar (2)
Teunissen, Charlotte ... (2)
Schott, J. M. (2)
Kumar, D. (2)
Andreasson, Ulf, 196 ... (2)
Carter, SF (2)
Scholl, M (2)
Palmer, Colin N. A. (2)
Zetterberg, Henrik (2)
Verbeek, Marcel M (2)
Mattsson, Niklas (2)
Ashton, Nicholas J. (2)
Schöll, M (2)
Pereira, JB (2)
Palmer, CNA (2)
Wild, Edward J (2)
Rojas, Julio C. (2)
Hanrieder, Jörg (2)
van Wieringen, Wesse ... (2)
Tijms, Betty M (2)
Alvarez-Cermeño, Jos ... (2)
Fialová, Lenká (2)
Frederiksen, Jette L (2)
Meeter, Lieke H (2)
Mehta, Sanjay R (2)
Pérez-Santiago, Josu ... (2)
Pijnenburg, Yolande ... (2)
visa färre...
Lärosäte
Göteborgs universitet (20)
Lunds universitet (6)
Chalmers tekniska högskola (4)
Karolinska Institutet (4)
Uppsala universitet (2)
Umeå universitet (1)
visa fler...
Örebro universitet (1)
visa färre...
Språk
Engelska (27)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (19)
Naturvetenskap (6)

År

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy